Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants to 17 new non-executive employees under its 2019 Inducement Plan. Each employee received non-qualified stock options to purchase 199,000 shares at an exercise price of $1.02 per share, corresponding to the closing price on July 1, 2022. The options will vest over four years, contingent on continued employment. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management globally.
Senseonics Holdings, Inc. has received CE Mark approval for the Eversense® E3 CGM System, allowing commercialization in select European markets. The E3 system is the longest-lasting continuous glucose monitoring device, with a wear duration of up to 6 months and superior accuracy. Ascensia Diabetes Care, Senseonics’ commercial partner, will launch the product in Germany, Italy, Spain, and other EU countries starting Q3 2022. The E3 system enhances operational efficiency and supports non-adjunctive use, improving treatment decisions without confirmatory fingerstick tests.
Senseonics Holdings, Inc. (AMEX: SENS) announced its participation in the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022, at 1:30pm ET. The presentation will be accessible via a live and recorded webcast on the company's website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, including Eversense® devices, designed to aid diabetes management. The company aims to transform lives by providing innovative glucose monitoring solutions.
Senseonics Holdings, Inc. (AMEX: SENS) has announced its participation in the hybrid H.C. Wainwright Global Investment Conference on May 24, 2022. Management will engage in virtual one-on-one meetings, with a webcast presentation starting at 7:00 AM ET. The company specializes in implantable continuous glucose monitoring (CGM) systems, aimed at enhancing diabetes management. Their products include Eversense®, Eversense® XL, and Eversense® E3, which transmit glucose data to smartphones every five minutes.
Senseonics Holdings, Inc. (SENS) reported Q1 2022 financial results, showcasing total revenue of $2.5 million, a decrease from $2.8 million in Q1 2021. U.S. revenue rose to $0.8 million, while international revenue dropped to $1.7 million. The net income for Q1 2022 was reported at $86.7 million, significantly higher than the net loss of $249.5 million in Q1 2021, primarily due to adjustments in embedded derivatives. The gross profit remained stable at $0.5 million, though expenses increased due to R&D and operational costs. The company anticipates full-year 2022 net revenue between $14 million and $18 million.
Senseonics Holdings, Inc. (SENS) plans to release its first quarter 2022 financial results after market close on May 10, 2022. A conference call to discuss its performance will start at 4:30 p.m. ET on the same day, accessible via a dedicated webcast on their website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management, with products like Eversense® and Eversense® E3, which automatically send glucose data to smartphones every 5 minutes.
Senseonics Holdings, Inc. (AMEX: SENS) has announced the successful implantation of the first patient with the Eversense® E3 Continuous Glucose Monitoring (CGM) System in the U.S. This system, which received FDA approval in February, offers a 6-month sensor life, making it the longest-lasting CGM available. It features exceptional accuracy with a mean absolute relative difference (MARD) of 8.5%, reduced calibration frequency, and discreet on-body alerts. The Eversense E3 marks a significant advancement in diabetes care, enabling patients to manage their condition with improved confidence and convenience.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced equity grants to 17 new employees under its 2019 Inducement Plan. On April 1, 2022, the Compensation Committee granted non-qualified stock options for an aggregate of 142,000 shares at an exercise price of $1.94, reflecting the closing stock price on that date. The options will vest over four years, contingent on the employees' continued service. Senseonics aims to expand its Eversense CGM System to more diabetes patients in the U.S. and globally, enhancing their product offerings.
Senseonics Holdings, Inc. (SENS) reported its financial results for Q4 and the full year 2021. The fourth quarter total revenue reached $4.0 million, a slight increase from $3.9 million in Q4 2020. The significant net income of $84.4 million contrasts sharply with a net loss of $101.6 million in Q4 2020. Full-year revenue surged to $13.7 million, up from $4.9 million in 2020, driven by post-Covid sales and the transition of Eversense commercialization to Ascensia. Looking forward, the 2022 global revenue outlook is estimated between $14.0 million and $18.0 million.
Senseonics Holdings, Inc. (AMEX: SENS) will release its fourth quarter and full year 2021 financial results on March 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss performance details. Investors can access the call by dialing specific numbers or through a webcast on the company’s website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems, with products like Eversense® and Eversense® E3 designed to enhance diabetes management.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
